.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Multiple myeloma (MM) remains a significant clinical challenge due to its incurable nature and complex genetic landscape. While therapeutic advances have improved outcomes for many, patients with high-risk cytogenetics continue to face poor prognoses. Consequently, medical researchers are focusing on the JAM-A peptide inhibitor as a potential breakthrough for these aggressive subgroups. Recent evidence highlights chromosome 1q abnormalities as a critical driver of disease progression in multiple myeloma.
The F11R gene, which is located on chromosome 1q, codes for the Junctional Adhesion Molecule-A (JAM-A) protein. In patients with gains or amplifications of chromosome 1q, F11R expression is significantly elevated. This upregulation strongly correlates with poorer overall survival and a higher burden of circulating CD138 cells. Moreover, these circulating cells often serve as an early indicator of extramedullary disease. Since JAM-A promotes tumorigenic behavior through adhesion-dependent signalling, it has become a high-priority target for drug development.
To address this therapeutic gap, scientists utilized structure-based rational design to develop novel peptides. These molecules selectively disrupt JAM-A cis-dimerization, thereby halting the signalling pathways that support cancer cell survival. Notably, the candidate JAM-A peptide inhibitor known as P4 demonstrated potent anti-proliferative and pro-senescence effects in laboratory settings. Furthermore, in vivo testing using xenograft models confirmed that P4 significantly inhibits the growth of plasmacytoma-like tumours. These findings offer a strong rationale for transitioning this technology into clinical trials.
The emergence of JAM-A as a druggable target marks a pivotal shift in managing high-risk multiple myeloma. By specifically targeting the adhesive mechanisms of malignant plasma cells, clinicians may eventually overcome the resistance associated with 1q abnormalities. Additionally, soluble JAM-A levels could potentially serve as a non-invasive biomarker for patient stratification. Therefore, the continued development of JAM-A targeted therapies represents a promising horizon for improving long-term outcomes in hematological oncology.
JAM-A promotes the adhesion and migration of malignant plasma cells within the bone marrow. This interaction facilitates tumor growth, drug resistance, and the dissemination of cancer cells to extramedullary sites.
The P4 peptide is a rationally designed inhibitor that specifically targets JAM-A cis-dimerization. Unlike broader therapies, it selectively disrupts the protein's ability to form dimers, which is essential for its oncogenic adhesive signalling.
Yes, gains or amplifications of chromosome 1q are among the most frequent cytogenetic abnormalities in multiple myeloma. It is increasingly recognized as a major high-risk factor that dictates aggressive disease behavior and poor response to standard treatments.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
McAuley N et al. Junctional Adhesion Molecule-A (JAM-A) Associates With High-Risk Disease in Multiple Myeloma Patients and a Structure-Based Rationally-Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo. Eur J Haematol. 2026 May 27. doi: 10.1111/ejh.70225. PMID: 42204384.
Solimando AG et al. JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia. 2018 Mar;32(3):736-743. doi: 10.1038/leu.2017.287.
Giri S et al. The clinical significance of chromosome 1 abnormalities in newly diagnosed multiple myeloma. Blood Adv. 2020 Sep 8;4(17):4244-4253. doi: 10.1182/bloodadvances.2020002146.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research identifies JAM-A as a therapeutic target in high-risk multiple myeloma, showing promising results with the novel P4 peptide inhibitor....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
